Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 14/20 | 0.63 |
| ▸ | CRBN | Q96SW2 | 14/20 | 0.63 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.63 |
| ▸ | TNF | P01375 | 1/20 | 0.63 |
| ▸ | IL1B | P01584 | 1/20 | 0.63 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.63 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.63 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3741686 | 0.88 | DDB1 (0.64) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL22930395 | 0.85 | CRBN (0.64) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL12041911 | 0.85 | CRBN (0.64) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL4081888 | 0.84 | CRBN (0.58) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19370815 | 0.83 | DDB1 (0.57) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL3753913 | 0.83 | DDB1 (0.53) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL6541103 | 0.81 | DDB1 (0.56) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL3745321 | 0.80 | DDB1 (0.70) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL3739212 | 0.80 | DDB1 (0.55) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL29923654 | 0.80 | CRBN (0.80) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1341537-B1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2007-01-24 | — | — | EP | claimed |
| EP-1733726-A1 | Pharmaceutically active isoindoline derivatives | Celgene Corporation (US) | 2006-12-20 | — | — | EP | claimed |
| US-6762195-B2 | TREATING DISEASES MEDIATED BY TUMOR NECROSIS FACTOR; INHIBIT ANGIOGENESIS AND TREATMENT OF CANCER, INFLAMMATORY, AND AUTOIMMUNE DISEASES | CELGENE CORPORATION | 2004-07-13 | — | — | US | claimed |
| US-20040122052-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION | 2004-06-24 | — | — | US | claimed |
| EP-1341537-A4 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2004-01-28 | — | — | EP | claimed |
| EP-1341537-A2 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2003-09-10 | — | — | EP | claimed |
| US-20030069428-A1 | Pharmaceutically active isoindoline derivatives | MULLER GEORGE | 2003-04-10 | — | — | US | claimed |
| WO-2002094180-A2 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2002-11-28 | — | — | WO | claimed |
| US-6458810-B1 | TREATMENT OF DISEASE STATES MEDIATED BY, TNF.ALPHA.. A TYPICAL EMBODIMENT IS TUMOR NECROSIS FACTOR FOR CANCER TREATMENT | CELGENE CORPORATION | 2002-10-01 | — | — | US | claimed |
| US-7834033-B2 | Methods for treating cancer using 3-[1,3dioxo-4-benzamidoisoindolin-2-yl]-2,6-dioxo-5-hydroxypiperidine | CELGENE CORPORATION (US) | 2010-11-16 | — | — | US | disclosed |
| EP-1733726-B1 | Pharmaceutically active isoindoline derivatives | CELGENE CORP (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1733726-B1 | Pharmaceutically active isoindoline derivatives | CELGENE CORP (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1341537-B1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1733726-A1 | Pharmaceutically active isoindoline derivatives | Celgene Corporation (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20040122052-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION | 2004-06-24 | — | — | US | disclosed |
| EP-1341537-A4 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1341537-A2 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030069428-A1 | Pharmaceutically active isoindoline derivatives | MULLER GEORGE | 2003-04-10 | — | — | US | disclosed |
| WO-2002094180-A2 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2002-11-28 | — | — | WO | disclosed |
| US-6458810-B1 | TREATMENT OF DISEASE STATES MEDIATED BY, TNF.ALPHA.. A TYPICAL EMBODIMENT IS TUMOR NECROSIS FACTOR FOR CANCER TREATMENT | CELGENE CORPORATION | 2002-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122052-A1 | Pharmaceutically active isoindoline derivatives | TNF, RELA, NFKBIA | DDB1 2659/4885CRBN 4232/4885IKZF3 109/4885 |
| US-20030069428-A1 | Pharmaceutically active isoindoline derivatives | TNF, RELA, NFKBIA | DDB1 2659/4885CRBN 4232/4885IKZF3 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.